Division of Endocrinology, Hospital de Clínicas José de San Martín (UBA), University of Buenos Aires, Córdoba 2351, 5th floor, Buenos Aires, C 1120, Argentina.
Rev Endocr Metab Disord. 2024 Feb;25(1):79-93. doi: 10.1007/s11154-023-09857-7. Epub 2023 Nov 28.
The current approach for patients with differentiated thyroid carcinoma should be individualized according to the risk of recurrence, and this stratification could be used to identify the risk of persistent/recurrent disease in three scenarios: preoperatively, immediately postoperatively, and during long-term follow-up. The initial risk of recurrence will tailor the management of the patient in the preoperative and immediate postoperative settings, while the dynamic risk, which considers the responses to treatment, could guide the decision-making process for remnant ablation and long-term management.This review provides a summary of the existing information regarding the dynamic risk of recurrence and recommended management for patients with differentiated thyroid cancer. The application of this approach is essential to avoid unnecessary treatments for most patients who will have a favorable prognosis. On the other hand, it allows specific therapeutic interventions for those patients at high risk of recurrence. In the future, analysis of tumor biology and prospective studies will surely improve the accuracy of recurrence risk prediction.
对于分化型甲状腺癌患者,目前的治疗方法应根据复发风险进行个体化,这种分层可用于识别三种情况下持续性/复发性疾病的风险:术前、术后即刻和长期随访期间。复发的初始风险将调整术前和术后即刻患者的管理,而动态风险(考虑治疗反应)可以指导残余消融和长期管理的决策过程。本综述总结了关于分化型甲状腺癌患者复发动态风险的现有信息,并推荐了相应的管理措施。这种方法的应用对于避免大多数预后良好的患者进行不必要的治疗至关重要。另一方面,它允许对复发风险高的患者进行特定的治疗干预。未来,肿瘤生物学分析和前瞻性研究肯定会提高复发风险预测的准确性。